Aspire Biopharma Holdings, Inc.

• Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise

• Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems

• Augments revenue growth profile and diversifies Aspires' development and commercial portfolio with new high growth business

• Expected to immediately improve path to profitability

New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.

Clopidogrel, currently sold under the brand name Plavix®, was the 41^st most commonly prescribed medication in the United States, with more than 15.2 million combined branded and generic prescriptions in 2023

Strategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine technology

New streamlined, mobile-optimized shopping experience, allows consumers to purchase BUZZ BOMB™ directly, access exclusive promotions and engage with the brand through educational and lifestyle content highlighting the benefits of sublingual delivery

• New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized anxiety disorders

• Alprazolam, sold under the brand name Xanax® among others, was the 37th most commonly prescribed medication in the United States, with more than 15.8 million combined branded and generic prescriptions in 2023

• Phase 1 clinical trial planned for mid-2026

• In partnering with Aspire's BUZZ BOMB™ brand, Ashley joins a decorated athlete and fitness trainer roster fueled by the brand's industry-leading commitment to innovation